Jason Butler
Stock Analyst at Citizens
(4.68)
# 159
Out of 5,122 analysts
141
Total ratings
52.74%
Success rate
46.56%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $4.49 | +78.37% | 2 | Jan 5, 2026 | |
| CYTK Cytokinetics | Maintains: Market Outperform | $78 → $88 | $63.52 | +38.54% | 17 | Dec 22, 2025 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $5.80 | +227.59% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $113.57 | +15.35% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $8.89 | +113.72% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $77.93 | +18.05% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.00 | +200.00% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $26.44 | +5.92% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $24.23 | +52.70% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.54 | +150.97% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.56 | +31.58% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $27.27 | +266.70% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $30.37 | +25.12% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.94 | +101.34% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.42 | +16.96% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $850.87 | -17.61% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $15.51 | +112.83% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $2.91 | +209.28% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.84 | +142.35% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.67 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $7.37 | +569,777.88% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $13.48 | +760.53% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.88 | +131.96% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.48 | - | 1 | Dec 2, 2020 |
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $4.49
Upside: +78.37%
Cytokinetics
Dec 22, 2025
Maintains: Market Outperform
Price Target: $78 → $88
Current: $63.52
Upside: +38.54%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $5.80
Upside: +227.59%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $113.57
Upside: +15.35%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $8.89
Upside: +113.72%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $77.93
Upside: +18.05%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.00
Upside: +200.00%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $26.44
Upside: +5.92%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $24.23
Upside: +52.70%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.54
Upside: +150.97%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.56
Upside: +31.58%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $27.27
Upside: +266.70%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $30.37
Upside: +25.12%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.94
Upside: +101.34%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.42
Upside: +16.96%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $850.87
Upside: -17.61%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $15.51
Upside: +112.83%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $2.91
Upside: +209.28%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.84
Upside: +142.35%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.67
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $7.37
Upside: +569,777.88%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $13.48
Upside: +760.53%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.88
Upside: +131.96%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.48
Upside: -